This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
A hefty 63% of healthcare providers are grappling with revenue cycle management ...
Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reporte...
A meeting of outside experts to discuss the FDA’s post-marketing requirements fo...
The company will use the funds for AI research and to advance its programs in cl...
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell t...
Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survi...
Vancouver-based WELL Health will assume control of HEALWELL AI upon the closing ...
Vancouver-based WELL Health will assume control of HEALWELL AI upon the closing ...
New data unveiled Monday showed that Merck’s Winrevair can significantly cut the...
AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believi...
The departure of one of the FDA’s highest-profile regulators, whose career was d...
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could b...
For the 163rd episode of the Healthcare IT Today Podcast, we are recapping the r...
Plus, news about Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine redu...
Google’s bet on AI in drug discovery just got a lot bigger. Isomorphic Labs ...
A New York City drug developer led by well-known executives and backed by some o...